- Home
- ICON vs RDHL Comparison
ICON vs RDHL Comparison
Compare ICON & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- RDHL
- Stock Information
- Founded
- ICON 2023
- RDHL 2009
- Country
- ICON Greece
- RDHL Israel
- Employees
- ICON N/A
- RDHL N/A
- Industry
- ICON
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- RDHL Health Care
- Exchange
- ICON Nasdaq
- RDHL Nasdaq
- Market Cap
- ICON 4.7M
- RDHL 3.9M
- IPO Year
- ICON 2024
- RDHL N/A
- Fundamental
- Price
- ICON $0.83
- RDHL $1.04
- Analyst Decision
- ICON Strong Buy
- RDHL
- Analyst Count
- ICON 1
- RDHL 0
- Target Price
- ICON $4.50
- RDHL N/A
- AVG Volume (30 Days)
- ICON 42.6K
- RDHL 1.5M
- Earning Date
- ICON 10-31-2025
- RDHL 09-05-2025
- Dividend Yield
- ICON 100.00%
- RDHL N/A
- EPS Growth
- ICON N/A
- RDHL N/A
- EPS
- ICON N/A
- RDHL N/A
- Revenue
- ICON $6,137,000.00
- RDHL $9,550,000.00
- Revenue This Year
- ICON $94.05
- RDHL $381.91
- Revenue Next Year
- ICON $18.81
- RDHL N/A
- P/E Ratio
- ICON N/A
- RDHL N/A
- Revenue Growth
- ICON 25.60
- RDHL 157.62
- 52 Week Low
- ICON $0.70
- RDHL $1.01
- 52 Week High
- ICON $130.80
- RDHL $8.75
- Technical
- Relative Strength Index (RSI)
- ICON 11.93
- RDHL 33.14
- Support Level
- ICON $0.70
- RDHL $1.01
- Resistance Level
- ICON $1.33
- RDHL $1.07
- Average True Range (ATR)
- ICON 0.13
- RDHL 0.09
- MACD
- ICON -0.03
- RDHL 0.01
- Stochastic Oscillator
- ICON 11.60
- RDHL 5.26
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.